Erratum: Tipifarnib in Head and Neck Squamous Cell Carcinoma with HRAS Mutations (J Clin Oncol (2021) DOI: 10.1200/JCO.20.02903)

Allan L. Ho, Irene Brana, Robert Haddad, Jessica Bauman, Keith Bible, Sjoukje Oosting, Deborah J. Wong, Myung Ju Ahn, Valentina Boni, Caroline Even, Jerome Fayette, Maria José Flor, Kevin Harrington, Sung Bae Kim, Lisa Licitra, Ioanna Nixon, Nabil F. Saba, Stephan Hackenberg, Pol Specenier, Francis WordenBinaifer Balsara, Mollie Leoni, Bridget Martell, Catherine Scholz, Antonio Gualberto

Research output: Contribution to journalComment/debate

Abstract

David S. Hong should have appeared in the AUTHORS' DISCLOSURES OF POTENTIAL CONFLICT OF INTEREST list as follows: David S. Hong Stock and Other Ownership Interests: OncoResponse, Telperian.

Original languageEnglish
Pages (from-to)3192-3193
Number of pages2
JournalJournal of Clinical Oncology
Volume39
Issue number28
DOIs
StatePublished - Oct 1 2021

Fingerprint

Dive into the research topics of 'Erratum: Tipifarnib in Head and Neck Squamous Cell Carcinoma with HRAS Mutations (J Clin Oncol (2021) DOI: 10.1200/JCO.20.02903)'. Together they form a unique fingerprint.

Cite this